Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study

Archives of Medical Science

Volumn 11, Issue 2, 2015, Pages 353-361

  Stawczyk Eder, Kamila ^a   Eder, Piotr ^a   Lykowska Szuber, Liliana ^a   Krela Kazmierczak, Iwona ^a   Klimczak, Katarzyna ^a   Szymczak, Aleksandra ^a   Szachta, Patrycja ^b   Katulska, Katarzyna ^a   Linke, Krzysztof ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Institute of Microecology   (Poland)

Author keywords

Disease activity; Endoscopy; Inflammatory bowel diseases; Magnetic resonance enterography

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; FECAL CALPROTECTIN; HEMOGLOBIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENDOSCOPY; FEMALE; FOLLOW UP; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE COUNT;

EID: 84928399624     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.43672     Document Type: Article

References (30)

1. Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease. Dig Dis Sci 2011; 56: 2372-7.
2. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome Criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-60.
3. Meucci G, D'Inca R, Maieron R, et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: a multicenter prospective study. Dig Liver Dis 2010; 42: 191-5.
4. Van Rheenen P, Van de Vijer E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
5. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-9.
6. Aomatsu T, Yoden A, Matsumoto K, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci 2011; 56: 2372-7.
7. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's Disease Activity Index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40-6.
8. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008; 28: 1221-9.
9. Kostakis ID, Cholidou KG, Vaiopolous AG, Vlachos IS, Perrea D, Vaos G. Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review. Dig Dis Sci 2013; 58: 309-19.
10. Tibble J, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
11. Gisbert JP, Bermejo F, Perez-Calle LZ, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190-8.
12. Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci 2006; 10: 17-22.
13. Ryan JD, Silverberg MS, Xu W, et al. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther 2013; 38: 274-83.
14. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
15. Sipponen T, Haapamaki J, Savilahti E, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol 2012; 47: 778-84.
16. Best WR, Becktel JM, Singelton JW, Kern Jr F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
17. Eder P, Katulska K, Łykowska-Szuber L, Stawczyk-Eder K, Krela-Kazmierczak I, Linke K. Simple Enterographic Activity Score for Crohn's Disease - comparison with endoscopic, clinical and biochemical findings. Pol Arch Med Wewn 2013; 7-8: 378-85.
18. Daperno M, D'Haens G, van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12.
19. Lovasz BD, Lakatos L, Horvath A, et al. Evolution of disease phenotype in adult and pediatric onset Crohn's disease in population-based cohort. World J Gastroenterol 2013; 19: 2217-26.
20. Chevaux JB, Vavricka SR, Rogler G, et al. Mucosal healing with anti-TNF antibodies. Digestion 2012; 86 Suppl 1: 16-22.
21. Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn's disease patients with poor prognosis. Expert Rev Clin Immunol 2013; 9: 65-75.
22. Ehteshami-Afshar S, Nikfar S, Rezaie A, Abdollahi M. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci 2011; 7: 1000-12.
23. Terheggen G, Lanyi B, Schanz S, et al. Safety, feasibility, and tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy 2008; 40: 656-63.
24. Amitai MM, Ben-Horin S, Eliakim R, Kopylov U. Magnetic resonance enterography in Crohn's disease: a guide to common imaging manifestations for the IBD physician. J Crohns Colitis 2013; 7: 603-15.
25. Koulaouzidis A, Douglas S, Rogers MA, Arnott ID, Plevris JN. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand J Gastroenterol 2011; 46: 561-6.
26. Koulaouzidis A, Douglas S, Plevris JN. Lewis score correlates more closely with fecal calprotectin than Capsule Endoscopy Crohn's Disease Activity Index. Dig Dis Sci 2012; 57: 987-93.
27. Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol 2011; 46: 694-700.
28. Freeman HJ. Use of the Crohn's Disease Activity Index in clinical trials of biological agents. World J Gastroenterol 2008; 14: 4127-30.
29. Lahiff C, Safaie P, Awais A, et al. The Crohn's Disease Activity Index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2013; 37: 786-94.
30. Łodyga M, Eder P, Bartnik W, et al. Guidelines for the management of Crohn's disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. Prz Gastroenterol 2012; 7: 317-38.